Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Consolidated Net Income: 2011-2025

Historic Consolidated Net Income for Ani Pharmaceuticals (ANIP) over the last 14 years, with Sep 2025 value amounting to $26.6 million.

  • Ani Pharmaceuticals' Consolidated Net Income rose 210.07% to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year increase of 671.57%. This contributed to the annual value of -$18.5 million for FY2024, which is 198.63% down from last year.
  • Ani Pharmaceuticals' Consolidated Net Income amounted to $26.6 million in Q3 2025, which was up 212.02% from $8.5 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Consolidated Net Income high stood at $26.6 million for Q3 2025, and its period low was -$24.2 million during Q3 2024.
  • Its 3-year average for Consolidated Net Income is $4.6 million, with a median of $6.2 million in 2023.
  • In the last 5 years, Ani Pharmaceuticals' Consolidated Net Income slumped by 18,372.73% in 2022 and then spiked by 1,135.21% in 2024.
  • Ani Pharmaceuticals' Consolidated Net Income (Quarterly) stood at -$24.1 million in 2021, then spiked by 82.35% to -$4.3 million in 2022, then skyrocketed by 127.12% to $1.2 million in 2023, then tumbled by 989.70% to -$10.3 million in 2024, then surged by 210.07% to $26.6 million in 2025.
  • Its last three reported values are $26.6 million in Q3 2025, $8.5 million for Q2 2025, and $15.7 million during Q1 2025.